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The aberrant expression of PSMD10 has important functions in various malignancies. This study
showed that PSMD10 was highly expressed and inversely correlated with the expression of miR-
605 in intrahepatic cholangiocarcinoma (ICC) specimens. MiR-605 directly targeted and repressed
PSMD10 expression. In addition, over-expression of miR-605 inhibited ICC cell progression both
in vitro and in vivo. This effect of miR-605 on ICC cells was similar to that of PSMD10 knock-down
by RNAi. Moreover, restoration of PSMD10 could reverse the phenotypic alteration caused by miR-
605 in ICC cells. These results suggest a new therapeutic strategy in ICC by restoring miR-605, which
is regulated by p53.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary epithelial tumor arising from the epithelium of
the intrahepatic bile duct. ICC is a treatment refractory malignancy
with a high mortality and increasing incidence worldwide
[1–3]. However, the molecular etiology of ICCs remains unclear.
The proto-oncogene, proteasome 26S subunit non-ATPase 10
(PSMD10), which encodes a subunit of the PA700/19S complex,
has important functions in the pathogenesis of cancer. Dysregula-
tion of PSMD10 expression contributes to cancer progression, and
has essential functions in cell survival, migration, and proliferation
[4–6]. Early studies have shown that PSMD10 enhances the ubiqui-
tylation and degradation of p53, which is often mutated in ICC
[7–9]. PSMD10 has become an important therapeutic target for
ICC. Therefore, a promising therapeutic strategy against ICC should
be developed, and a better understanding of the molecular regula-
torymechanism of PSMD10may be helpful for the treatment of ICC.
MicroRNAs (miRNAs) are a class of small non-coding RNAs that
negatively regulate gene expression at the post-transcription levelby mRNA degradation and translation inhibition through binding
the 30 untranslated regions (UTRs) of human mRNAs [10]. In the
past decade, miRNA has been reported to be dysregulated in
tumors. MiRNAs act as potent oncogenes or tumor suppressor
genes [11–13]. The dysregulation of miRNAs has also been
reported to be responsible for ICC tumor progression. For example,
miR-204 and miR-320 are lowly expressed in ICC, and over-expres-
sion of miR-204 and miR-320 can induce chemotherapeutic drug-
triggered apoptosis and down-regulate the expression of BCL-2 and
Mcl-I, respectively[14]. Down-regulation of miR-214 contributes to
ICC metastasis by targeting Twist [15]. However, little is known
about PSMD10-related miRNAs in ICC.
In this study, we aimed to investigate whether the expression of
PSMD10 is regulated by miR-605, which is a target of p53 for tran-
scriptional activation [16]. Furthermore, the biological function of
dysregulated miR-605 and PSMD10 in ICC was investigated. The
results of this study could elucidate the mechanism of miRNA in
ICC.2. Materials and methods
2.1. Human tissue specimens, cell culture, and transfections
Twenty paired human ICC tissues and paired adjacent normal
parts were obtained from Southwest Hospital, Third Military
3492 J. Li et al. / FEBS Letters 588 (2014) 3491–3500Medical University with documented informed consent in each
case. All samples conﬁrmed by pathology were collected and fro-
zen in liquid nitrogen. RBE cells were purchased from the Chinese
Academy of Sciences Type Culture Collection (Shanghai, China),
and QBC939 was obtained from the XiangYa Central Experiment
Laboratory (Hunan, China). Cells were maintained in RPMI 1640
medium (GIBCO, NY, USA) containing 10% fetal bovine serum
(FBS; Sigma–Aldrich, St Louis, USA). Cells were grown in an incuba-
tor at 37 C and 5% carbon dioxide. All transfections were per-
formed using Lipofectamine 2000 (Invitrogen, CA, USA) according
to the manufacturer’s instructions.
2.2. RNA extraction and quantitative reverse transcription PCR (qRT-
PCR)
Total RNA from cells or tissue samples was isolated using Trizol
(Invitrogen, Grand Island, NY, USA) according to the manufac-
turer’s instructions. The RNAs were mixed with oligo (dT) or
miRNA-speciﬁc stem-loop RT primers, and reverse transcribed to
cDNA using M-MLV Reverse Transcriptase (Promega, Madison,
WI, USA). These cDNAs were used to analyze the expression of
miR-605, miR-875-3p, and PSMD10 by qPCR using an SYBR premix
Ex Taq kit (TaKaRa, Dalian, China). Paired primers (PSMD10-semi-F
and PSMD10-semi-R) were used to determine PSMD10 mRNA
expression, and the level of GAPDH mRNA was used as an endog-
enous control. After RT by miRNA speciﬁc RT primers, miRNA
speciﬁc forward primers (miR-605-Fwd and miR-875-3p-Fwd)
and the universal reverse primer (Rev) were used to analyze the
expression of miR-605 and miR-875-3p. U6 snRNA was used for
normalization. All reactions were performed in an ABI 7500 system
(Applied Biosystems, Foster, CA, USA) in triplicate, and the levels of
gene expression were calculated using the 2DDCt method. All
primers, purchased from Genewiz Biotechnologies (Suzhou, China),
are shown in Table 1.
2.3. Western blot analysis
Total proteins from clinical tissues and ICC cells were prepared
using RIPA buffer (Beyotime, Jiangsu, China). The proteins wereTable 1
Primers used in the experiments.
Primer name Primer seq
miR-559-F 50 CGCGGA
miR-559-R 50 CCGGAA
miR-605-F 50 CGCGGA
miR-605-R 50 CCGGAA
miR-875-3p-F 50 CGCGGA
miR-875-3p-R 50 CCGGAA
miR-1254-F 50 CGCGGA
miR-1254-R 50 CCGGAA
miR-605-ASO 50 TCTAAA
miR-605-RT 50 GTCGTA
miR-605-Fwd 50 TGCGGT
miR-875-3p-RT 50 GTCGTA
miR-875-3p-Fwd 50 TGCGGC
U6-RT 50 GTCGTA
U6-Fwd 50 TGCGGG
Rev 50 CCAGTG
PSMD10-CDS-F 50 CCGGAA
PSMD10-CDS-R 50 CCCAAG
PSMD10-semi-F 50 CGGGAA
PSMD10-semi-R 50 GCCGCA
PSMD10-UTR-Top 50 CTAGC A
PSMD10-UTR-Bot 50 TCGAC G
M-PSMD10-UTR-Top 50 CTAGC A
M-PSMD10-UTR-Bot 50 TCGACG
Sh-PSMD10-Top 50 GATCCG
Sh-PSMD10-Bot 50 AGCTTTquantiﬁed and separated in 10% SDS–PAGE gel, and transferred
to nitrocellulose membranes (Millipore, Bedford, MA, USA). The
membranes were probed with the following antibodies: mouse
anti-PSMD10 monoclonal antibody (Abcam, Cambridge, UK),
mouse anti-p53 monoclonal antibody (Abcam, Cambridge, UK),
and mouse anti-GAPDH monoclonal antibody (Abcam, Cambridge,
UK). GAPDH was used as a loading control. After incubation with
HRP-conjugated goat anti-mouse secondary antibody (Santa Cruz,
CA, USA), the proteins were visualized by an enhanced chemilumi-
nescence kit (Amersham Corp, Buckinghamshire, United Kingdom)
and exposed to chemiluminescent ﬁlm.2.4. Plasmid construction
To construct the expression plasmids of miR-559, miR-605,
miR-875-3p, and miR-1254, DNA fragments containing the
sequences of these miRNAs were ampliﬁed from HEK293 cell
DNA using speciﬁc primers (miR-559-F, miR-559-R, miR-605-F,
miR-605-R, miR-875-3p-F, miR-875-3p-R, miR-1254-F, and miR-
1254-R). All PCR products were then inserted into pcDNA3.1 at
the BamHI and EcoRI sites. The DNA fragments with wild-type
PSMD10 30 UTR and mutant PSMD10 30 UTR were synthesized
(Genewize, Suzhou, China), and inserted into pmirGLO dual-
luciferase reporter vector (Promega, Madison, WI, USA) using NheI
and SalI. To construct the PSMD10 expression plasmid, coding
sequences were ampliﬁed from the HEK293 cell cDNA library
using paired primers (PSMD10-CDS-F and PSMD10-CDS-R). The
DNA fragments were inserted into the pCMV6-neo vector using
EcoRI and HindIII. PSMD10 shRNA sequences were synthesized
(Genewize, Suzhou, China) and cloned into pSilencer2.1 vector by
BamHI and HindIII. All primer sequences are listed in Table 1.
2.5. Cell proliferation assay
RBE and QBC939 cells (5  103 cells/well) were plated in
96-well plates (Costar, CA, USA). After 24 h, cells were transfected
and incubated for another 24, 48, and 72 h. Cell viability was mea-
sured by MTT assays. For colony formation analysis, transfecteduence
TCCATCCTGGAGAACCTGTCC 30
TTCAGAGACAGGGTTTCACTG 30
TCCAGAGTGCTGAGATTGCAG 30
TTCCAGTTACGCCACATGAGG 30
TCCTCTGTAACTCTATGCATG 30
TTCAAATTCCTAGCATATACC 30
TCCTTCAACCCAAGGATACTG 30
TTCTGAACTACTGGGCTATAG 30
TCTCATAGTGCCTTCT 30
TCCAGTGCAGGGTCCGAGGTGCACTGGATACGACAGGAGAAG 30
AAATCCCATGGTGCCTTC 30
TCCAGTGCAGGGTCCGAGGTGCACTGGATACGACCACAACC 30
CTGGAAACACTGAGGAA 30
TCCAGTGCAGGGTCCGAGGTGCACTGGATACGACAAAATATGGAAC 30
TGCTCGCTTCGGCAGC 30
CAGGGTCCGAGGT 30
TTCATGGAGGGGTGTGTGTCTAAC 30
CTTTTAACCTTCCACCATTCTCTTG 30
GCTGGAAGAGTTG 30
ATATGAAGAGGAG 30
CAGCTTGGATTTATTCTTACTTTGTATGTTGTGTTGTTGTCCCCG 30
GGGACAACAACACAACATACAAAGTAAGAATAAATCCAAGCTGTG 30
CAGCTTCGTTATTTTCTTACTTTGTATGTTGTGTTGTTGTCCCCG 30
GGGACAACAACACAACATACAAAGTAAGAAAATAACGAAGCTGTG 30
GAGAGTATTCTGGCCGATTTCAAGAGAATCGGCCAGAATACTCTCCTTTTTTGGAAA 30
TCCAAAAAAGGAGAGTATTCTGGCCGATTCTCTTGAAATCGGCCAGAATACTCTCCG 30
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cells/well. After 10 d, cells were washed and stained with crystal
violet. Each group was repeated in triplicate.
2.6. Cell apoptosis
Cells were plated in six-well plates at a ﬁnal concentration of
6  105 cells/well. After 24 h, cell were transfected and grown
continuously for 48 h. After transfection, cells were washed in cold
PBS and trypsinized for apoptosis analysis using an Annexin V-PE/Fig. 1. MiR-605 is inversely correlated with PSMD10 and directly inhibits its expression i
MiRNA expression vectors and pcDNA3.1 control vector were transfected into RBE cells.
blot analysis. GAPDH was used for normalization. (C) Expression levels of miR-605, miR-
were used as the loading controls. (D) RBE cells were transfected with wild-type or mut
expression vector or pcDNA3.1 for 48 h. (E) Relationship between protein levels of miR-6
results from three experiments. ⁄P < 0.05.7-amino actinomycin D detection kit (BD Pharmingen, San Diego,
CA, USA) following the manufacturer’s protocol.
2.7. Cell migration assays
Cell migration analysis was performed using transwell cell cul-
ture inserts (Invitrogen, USA) coated with Matrigel. A total of
5  104 cells (in 0.2 ml of RPMI 1640 with 5% FBS) were seeded into
the upper chamber with 600 ll of RPMI1640 containing 5% FBS.
The bottom chamber was ﬁlled with DMEM containing 20% FBS.n ICC. (A) Bioinformatics prediction of four miRNAs that bind to PSMD10 30 UTR. (B)
Cells were harvested after 48 h, and PSMD10 expression was measured by Western
875-3p, and PSMD10 were analyzed by qRT-PCR and Western blot. U6 and GAPDH
ant PSMD10 30 UTR luciferase reporter vector only or co-transfected with miR-605
05 and PDMD10 were analyzed by Pearson’s correlation. The graph depicts averaged
Fig. 2. Effects of miR-605 on the proliferation, apoptosis, and migration of ICC cells. (A) RBE and QBC939 cells were transfected with miR-605 expression vector or pcDNA3.1
negative control plasmid. The expression of miR-605 was measured by qRT-PCR 48 h after transfection. (B) Cell viability was evaluated using MTT assays by measuring the
absorption at 570 nm. (C and D) Cells at 48 h post-transfection were subjected to detect colony formation (C) and migration ability (D) by colony formation and transwell
assays, respectively. (E) Cell apoptosis was analyzed by FACS after annexin V-PE/7-AAD staining. The experiments were repeated three times independently. ⁄P < 0.05.
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stained with crystal violet solution. The cells that migrated across
the membrane were counted in ﬁve random visual ﬁelds. All assays
were repeated in triplicate.
2.8. In vivo tumorigenesis assay
BALB/c nude mice (ﬁve-week old) were purchased from the
Animal Center of the Chinese Academy of Science (Shanghai,
China), and randomly assigned to one of four groups (10 miceper group). RBE or QBC939 cells (5  106 cells) transiently transfec-
ted with pcDNA3.1/pri-miR-605 or pcDNA3.1 were suspended in
100 ll of RPMI 1640, and injected subcutaneously in the right pos-
terior of mice. After 10 d, tumor growth was monitored and
recorded every 3 d. After 31 d, mice were sacriﬁced for evaluation.
2.9. Target prediction and luciferase activity assay
The DNA fragments of wild-type and mutant PSMD10 30 UTR
containing miR-605 binding region were cloned into the PmeI
Fig. 3. Knock-down of PSMD10 by RNAi shows similar negative regulation with miR-605 on ICC cells. (A) PSMD10 siRNA and control siRNA were transfected separately into
RBE and QBC939 cells. The PSMD10 protein level was detected by Western blot 48 h after transfection, and GAPDH was used as the loading control. (B) Cell viability was
evaluated using MTT assays 24, 48, and 72 h after transfection. (C and D) Cells at 48 h post-transfection were collected, and cell colony formation (C) and migration ability (D)
were evaluated by colony formation and transwell assays, respectively. (E) Cell apoptosis was analyzed by FACS after annexin V-PE/7-AAD staining. The experiments were
repeated three times independently. ⁄P < 0.05.
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reporter assays, cells were transfected with 30 UTR or mutant 30
UTR luciferase reporters only, or co-transfected with miR-605
expression vector and luciferase reporter. At 48 h after transfec-
tion, cells were harvested and analyzed using luciferase activity
in a Dual-Glo Luciferase Assay System (Promega, WI, USA). Nor-
malized ﬁreﬂy luciferase activity (ﬁreﬂy luciferase activity/Renilla
luciferase activity) for each construct was compared with that ofthe group of pmirGLO vector with the wild-type PSMD10 30 UTR.
Each assay was performed in triplicate.
2.10. Statistical analysis
Each experiment was performed in triplicate. All data are
presented as mean ± S.D. The difference between means was
analyzed with Student’s t-test, Non-parametric Mann–Whitney
Fig. 4. Ectopic expression of PSMD10 rescues the effects of miR-605 over-expression on ICC cells. (A) PSMD10 expression plasmid or pCMV6-Neo control vector were co-
transfected with miR-605 expression plasmid into RBE and QBC939 cells. Cells transfected with miR-605 expression plasmid only comprised the control group. The
expression of PSMD10 was detected by Western blot analysis. The GAPDH protein level was used as the loading control, and the relative expression is shown. (B–D) At 48 h
after transfection, the apoptosis (B), migration (C), and colony formation abilities (D) of the above groups were detected as mentioned previously. The experiments were
repeated three times independently. ⁄P < 0.05.
3496 J. Li et al. / FEBS Letters 588 (2014) 3491–3500U test or ANOVA. All tests performed were two-sided. P < 0.05
was considered to be statistically signiﬁcant.
3. Results
3.1. MiR-605 negatively regulates PSMD10 and is inversely correlated
with its expression in ICC
To investigate the candidate miRNAs that regulate the expres-
sion of PSMD10, computer algorithms were used. Four miRNAs,namely,miR-559,miR-605,miR-875-3p, andmiR-1254,were found
to contain the complementary nucleotides to the PSMD10 30 UTR
(Fig. 1A). We employed a gene over-expression approach to
examine the effect of these fourmiRNAs on PSMD10protein expres-
sion. RBE cells were transfected with miRNA over-expression vec-
tor, and PSMD10 protein expression was measured by Western
blot analysis. As shown in Fig. 1B, over-expression of miR-605 and
miR-875-3p signiﬁcantly suppressed PSMD10 expression. Further
studies on the expression of these two miRNAs and PSMD10 by
qRT-PCR indicated that only miR-605 was lowly expressed in
Fig. 5. MiR-605 inhibits tumor growth of ICC cells in a nude mice model. A total of 107 RBE or QBC939 cells continuously expressing miR-605 were suspended and injected
subcutaneously into the left anterior armpit of BALB/c nude mice. Tumor volume was monitored every 3 d. Photographs of dissected tumors from nude mice (A) and the
tumor growth curve (B) are shown. The expression levels of miR-605 (C) and PSMD10 protein (D) in these tumors were detected by qRT-PCR and Western blot analysis, with
U6 and GAPDH as the internal controls. The representative image and relative expression level are shown. ⁄P < 0.05.
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miR-605 directly binds to PSMD10 and leads to its dysregulation,
luciferase reporter assay was used.We constructed the pMIR repor-
ter luciferase vectors containing the wild-type or mutant putative
target site of the PSMD10 30 UTR, and transfected them into RBE
with miR-605 expression plasmid or pcDNA3.1 control vector. The
results show that miR-605 could signiﬁcantly down-regulate the
luciferase activities of the PSMD10 30 UTR reporter but not the
mutant PSMD10 30 UTR reporter relative to the negative control
group (Fig. 1D). Furthermore, the correlation of miR-605 andmRNA
level of PSMD10 also indicate thatmiR-605was inversely correlated
with PSMD10 mRNA (Fig. 1E, r = 0.6738) in ICC tissues. These
observations demonstrate that miR-605 could directly bind to the
30 UTR of PSMD10 and repressed its expression.
3.2. MiR-605 inhibits ICC cell proliferation and invasion in vitro
To investigate the function of miR-605 dysregulation in ICC, we
investigated the inﬂuence of miR-605 on the cell proliferation,
apoptosis, and migration of ICC cells by increasing the expression
level of miR-605 in RBE and QBC939 cell lines. qRT-PCR was per-
formed to analyze the expression of miR-605 in RBE and QBC939
cell lines (Fig. 2A). MTT (Fig. 2B) and colony formation (Fig. 2C)
results indicate that over-expression of miR-605 suppressed ICC
cell proliferation. We also detected the effect of miR-605 on ICC cell
migration by transwell assay. The results show that the number of
migrating cells decreased after transfection with miR-605
expression vector (Fig. 2D). Furthermore, results of FACS analysisindicate that the potency of apoptosis cells was higher in miR-605
over-expressing ICC cells than that in the control group (Fig. 2E).
These data indicate that miR-605 inhibited the cell proliferation,
induced cell apoptosis, and suppressed the migration of ICC cells
in vitro.
3.3. Knock-down of PSMD10 represses cell proliferation and induces
apoptosis of ICC cells
We discovered that miR-605 directly repressed PSMD10
expression and inhibited ICC cell progression. If this effect of
miR-605 is mediated by PSMD10, down-regulation of PSMD10 in
ICC cells will have similar results to miR-605. In this study, we
transfected PSMD10-speciﬁc shRNA plasmid to repress its expres-
sion in ICC cells (Fig. 3A). The results of MTT (Fig. 3B), colony
formation assay (Fig. 3C), and transwell analysis (Fig. 3D) indicate
that down-regulation of PSMD10 inhibited ICC cell proliferation. In
addition, FACS analysis results show that the quantity of apoptotic
cells was higher in down-regulated PSMD10 groups than that in
the control groups (Fig. 3E).
3.4. Restoration of PSMD10 reverses the phenotypic alteration caused
by miR-605 in ICC cells
To further conﬁrm whether the effect of miR-605 on ICC cells is
dependent on the repression of PSMD10 expression, we transfec-
ted PSMD10 expression vector into miR-605 over-expressing ICC
cells. Western blot analysis was performed to detect the expression
3498 J. Li et al. / FEBS Letters 588 (2014) 3491–3500of PSMD10 (Fig. 4A). Moreover, the cell proliferation and apoptosis
of cells were analyzed. The ectopic expression of PSMD10 could
rescue the increase in cell apoptosis (Fig. 4B), and inhibition of
migration (Fig. 4C) and colony formation ability (Fig. 4D) caused
by over-expression of miR-605. These data suggest that the effects
of miR-605 on ICC cells were achieved by directly inhibiting
PSMD10 expression.
3.5. MiR-605 suppresses ICC tumor growth in vivo
To test whether miR-605 has the same effect in vivo, RBE and
QBC939 cells transfected with miR-605 expression vectors or
pcDNA3.1 vectors were injected subcutaneously into BALB/c nude
mice, respectively. As shown in Fig. 5A and B, the tumor volume in
mice with highmiR-605 levels was smaller compared with those in
pcDNA3.1-transfected cells. The expression level of miR-605 in
tumor tissues of miR-605 expression vector transfection groups
was higher than that in the control groups (Fig. 5C), which was
consistent with the expression of PSMD10 (Fig. 5D). These data
suggest the suppression of miR-605 on ICC cell growth in vivo,
and indicate the tumor suppressor function of miR-605.
3.6. P53 indirectly inhibits PSMD10 expression in ICC cells
miR-605 has been conﬁrmed to be regulated by P53. To test
whether PSMD10 joins P53-miR-605 network. P53 expressionFig. 6. PSMD10 is a down-stream response element of the p53-dependent miR-605 reg
control ASO into RBE cells. Cells transfected with pcDNA3.1 vector only comprised the c
levels of p53 and PSMD10 48 h after transfection (A). The GAPDH protein level was used a
605 was analyzed by qRT-PCR, and U6 was used as the loading control. (D) A proposedplasmid was transfected independently or co-transfected with
miR-605 ASO or control ASO into RBE cells. Cells transfected with
pcDNA3.1 vector only was served as control. AS it shown in
Fig. 6A and B, The ectopic expression of P53 could up-regulate
P53 level but repress the expression of PSMD10 in RBE cells. While
the transfection of miR-605 ASO could restorate PSMD10 expres-
sion in P53 transfected cells. These data indicated that PSMD10 is
a member of P53_miR-605_PSMD10 feedback loop and regulate
ICC cell progression (Fig. 6D).
4. Discussion
Dysregulation of the PDMD10 pathway and miRNA has been
reported to be crucial for the development of tumor [4,5,17,18].
MiR-605 is located in chromosome 10q21.1. It has been reported
to be positively regulated by p53, and forms a p53-miR-605-
Mdm2 feedback loop in response to stress [16]. Early studies have
been shown that miR-605 was lowly expressed in lung cancer and
the mutant of miR-605 might be increase the risk of lung cancer
amongmales [19]. miRNAs are a class of non-coding RNAs that reg-
ulate cancer cell progression through their downstream target
genes. One miRNA can regulate various gene expression. Here we
have predicted some candidate target genes of miR-605. For exam-
ple, PSMD10, PDCD2, TGFBR1, RABL5, P21, CADM1, MDM2. These
genes are well known and play important role in Tumor biological
processes. Here we chose PSMD10, one crucial regulator in ICC, asulatory network. P53 expression plasmid was co-transfected with miR-605 ASO or
ontrol group. (A and B) Western blot analysis was performed to detect the protein
s the loading control, and the relative expression is shown (B). (C) Expression of miR-
model describing a miR-605-dependent pathway of PSMD10 regulation by p53.
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605 was lowly expressed in ICC tissues and inversely correlated
with the expression of PSMD10. Luciferase reporter assaysWestern
blot analysis showed that the expression of miR-605 could inhibit
the expression of PSMD10 in ICC cells by directly binding the 30
UTR of PSMD10. In addition, Ectopic expression of miR-605
resulted in the induction of cell apoptosis and inhibition of cell
proliferation and migration ability in vitro. Furthermore, the
results of xenograft indicate that miR-605 signiﬁcantly suppressed
ICC tumor growth in vivo, similar to the decreased level of PSMD10
protein. Thus, miR-605 may serve as a tumor suppressor in ICC
cells by inhibiting the proto-oncogene PAMD10.
PSMD10 is a component of the 26S proteasome, which is
required for ubiquitin-dependent protein degradation. The aber-
rant expression of PSMD10 has been found in colorectal cancer,
breast cancer, and liver cancer [4,20–22]. Aberrant PSMD10 expres-
sion has a function in tumor metastasis, proliferation, and drug
resistance [4,6,22–24]. The results of the present study suggest that
PSMD10 was directly targeted by miR-605. To verify that the effect
of miR-605 in ICC cells was mediated by PSMD10, RNAi technique
was used to repress PSMD10 expression. Knock-down of PSMD10
induced ICC cell apoptosis and inhibited cell proliferation and
migration. In addition, restoration of PSMD10 protein expression
counteracted the effects caused by over-expression of miR-605.
Thus, the anti-tumor function of miR-605 in ICC was mediated by
PSMD10.
P53 is a novel tumor suppressor gene and plays important role
in cancer genesis, proliferation and differentiation. The mutation of
P53 were reported in various type of cancer and may play a role in
the tumor growth pattern [25–28]. In contrast, some studies also
indicated the over-expression of P53 in ICC patients [29,30]. miR-
605 is positively regulated by P53, then miR-605 represses
Mdm2 expression, which results in the increase in p53 transcrip-
tional activity. In addition, PSMD10 can bind to Mdm2 and pro-
mote p53 degradation [7]. In the present study, we measured the
status of miR-605 and PSMD10 in ICC cells after transfection of
the p53 expression plasmid. The results show that increased p53
levels up-regulated the miR-605 levels and inhibited PSMD10
expression. Therefore, PSMD10 joined the p53 network to form a
p53:miR-605:PSMD10/Mdm2 positive feedback loop, and regu-
lated tumor progression.
In this study, we found that miR-605 was down-regulated and
directly inhibited the expression of PSMD10 in ICC. We also
showed that miR-605 inhibited cell proliferation, induced cell
apoptosis, and suppressed cell migration, suggesting a tumor sup-
pressor function in ICC mediated by PSMD10. These ﬁndings will
be helpful to improve understanding of p53-dependent tumor
regulation, and may represent a new therapeutic target for the
treatment of ICC.
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